@virtuosos2's peptide injury prevention claims, fact-checked

What did @virtuosos2 actually say?

The creator is discussing someone with a broken or severely damaged bone, urging them to try BPC-157, which they describe as something "so many people report feeling better" from, while also noting it's "very hard to get." The conversation then pivots to David Goggins, describing his decision to undergo a tibial osteotomy instead of a knee replacement, framing it as an extreme but admirable choice. No specific dosing, sourcing, or medical protocol is mentioned, but the implication is clear: BPC-157 is being floated as a useful recovery tool for serious musculoskeletal injury.

The Goggins discussion is largely anecdotal sports commentary, not medical advice. But the BPC-157 recommendation is where things get scientifically complicated and worth examining carefully.

Does the science back this up?

On BPC-157, the honest answer is: animal data looks interesting, human data is nearly nonexistent. The claim that "so many people report feeling better" is accurate as a description of anecdotal reports, but anecdote is not evidence. On the Goggins osteotomy description, the creator gets the basic surgical concept right.

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in gastric juice. Rodent studies have shown it promotes tendon-to-bone healing and reduces inflammation (Sikiric et al., 2018, Current Pharmaceutical Design). A 2021 review in Biomedicines noted BPC-157 influences nitric oxide pathways and growth factor signaling in connective tissue. However, no completed randomized controlled trials in humans have been published as of 2024. The FDA has not approved BPC-157 for any indication, and the compound is not legal in compounded form for human use following a 2022 FDA guidance update. The creator saying it's "very hard to get" is an understatement of the regulatory picture.

On the osteotomy: a high tibial osteotomy is a real, evidence-based procedure for younger, active patients with medial compartment osteoarthritis who want to delay or avoid total knee replacement. The creator's description of cutting a wedge and shifting bone geometry is a reasonable lay description of the procedure (Brouwer et al., 2014, Cochrane Database of Systematic Reviews).

What did they get wrong (or right)?

The creator gets partial credit here, but the BPC-157 framing has real problems. The osteotomy description is broadly accurate and the framing of Goggins as someone choosing function over comfort is fair sports commentary. The BPC-157 section is where skepticism is warranted.

Saying BPC-157 is "very useful" based on what people "report feeling" is exactly the kind of claim that bypasses the scientific process. Subjective reports are influenced by placebo effects, expectation bias, and the fact that musculoskeletal injuries often improve on their own over weeks to months. The creator does not claim BPC-157 treats or cures anything specifically, which keeps them out of the most dangerous territory, but recommending a compound with no human trial data to someone with what sounds like a serious fracture is irresponsible framing regardless of intent.

The regulatory piece is also glossed over. BPC-157 is not an FDA-approved drug. It was removed from the list of permissible compounded substances. Sourcing it currently means purchasing from research chemical suppliers, with no quality assurance, no standardized dosing, and no physician oversight in most cases. That context matters enormously when you're talking about a person with a broken bone.

What should you actually know?

If you're dealing with a serious musculoskeletal injury, the gap between "people say this helps" and "this is supported by evidence in humans" is not a small one. It is the entire difference between informed medical decision-making and experimenting on yourself.

BPC-157 research is ongoing, and the preclinical data is genuinely worth watching. Researchers like Sikiric have been publishing on this compound for decades, and the mechanistic rationale is plausible. But plausible is not proven. A 2023 review in the Journal of Orthopaedic Research noted that most peptide therapies showing promise in animal tendon and ligament models have historically struggled to replicate results in human trials due to differences in bioavailability, tissue penetration, and dosing windows.

For the Goggins osteotomy: this is a legitimate surgical option, but it is specifically indicated for patients who meet particular criteria, typically younger patients with isolated compartment disease, adequate bone stock, and realistic activity goals. It is not a universal alternative to knee replacement and comes with its own recovery demands and complication risks. Framing it as pure toughness overlooks that it is also a clinical decision made with a surgeon.

If you have a tendon or bone injury and are curious about peptide therapy, that conversation should happen with a physician who can evaluate your specific imaging, history, and risk profile, not on the basis of a TikTok clip.